Long-term clinical outcomes after drug eluting stent implantation with and without stent overlap.

Abstract

OBJECTIVE\nThe aim of this study was to investigate the impact of drug eluting stent (DES) overlap on clinical outcomes after percutaneous coronary intervention (PCI).\n\n\nBACKGROUND\nWhile the use of overlapping bare metal stent has been associated with an increased risk of adverse clinical events, the long-term impact of DES overlap on clinical outcomes is not certain at present. Similarly, the effect of different DES generations and polymer types on DES overlap associated clinical outcomes has not previously been comprehensively elucidated.\n\n\nMETHODS\nWe analyzed the angiographic and clinical outcomes of 5605 patients treated with DES in the setting of the ISAR-TEST 4 and ISAR-TEST 5 randomized control trials according to the presence or absence of stent overlap. The clinical endpoints assessed in this study were all-cause death, myocardial infarction (MI), target lesion revascularization (TLR), and definite or probable stent thrombosis at 10-years. We also compared rates of binary angiographic restenosis (BAR) at 6-8\xa0months.\n\n\nRESULTS\nAt 10\u2009years, all-cause mortality (Hazard ratios [HR]\xa0=\xa01.05 [0.95-1.16]; p\xa0=\xa00.348) did not differ between the stent overlap and no stent overlap groups. MI (8.4% vs. 5.2%; HR\xa0=\xa01.67 [1.35-2.07], p\u2009<\u20090.001) and TLR (23.7% vs. 16.3%; HR\xa0=\xa01.54 [1.36-1.74], p\u2009<\u20090.001) occurred more frequently in the stent overlap group. For MI, landmark analysis demonstrated that this increase in risk was primarily in the first 30\u2009days post PCI. BAR at 6-8\xa0months was also more frequent in the stent overlap group (16.0% vs. 10.3%; HR\xa0=\xa01.65 [1.41-1.92], p\u2009<\u20090.001).\n\n\nCONCLUSION\nDES overlap is associated with an increased risk of adverse clinical events post PCI.